SCHEMBL4255023

SCHEMBL4255023

CNC(=O)Nc1ccc(-c2sc3c(c2CN(C)Cc2ccccc2)c(=O)n(-c2ccccc2)c(=O)n3Cc2c(F)cccc2F)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GNRHR P30968 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4253402 0.94 GNRHR (1.00) GNRHR
Hydrochloric Acid SCHEMBL6644800 0.93 GNRHR (0.99) GNRHR
SCHEMBL1642713 0.93 GNRHR (1.00) GNRHR
Sufugolix SCHEMBL209021 0.92 GNRHR (1.00) GNRHR
Hydrochloric Acid SCHEMBL1644350 0.92 GNRHR (0.99) GNRHR
Sufugolix SCHEMBL4251869 0.92 GNRHR (0.99) GNRHR
SCHEMBL6644404 0.92 GNRHR (0.87) GNRHR
SCHEMBL8009377 0.91 GNRHR (1.00) GNRHR
SCHEMBL799481 0.91 GNRHR (0.83) GNRHR
SCHEMBL4053272 0.90 GNRHR (0.94) GNRHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090048273-A1 PREMATURE OVULATION PREVENTIVE AGENT TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-02-19 US disclosed
US-20080207524-A1 MEDICINAL PREPARATIONS FOR TREATING SEX HORMONE-DEPENDENT DISEASES TAKEDA PHARMACEUTICAL COMPANY LIMITED 2008-08-28 US disclosed
EP-1917978-A1 PREMATURE OVULATION PREVENTIVE AGENT Takeda Pharmaceutical Company Limited (JP) 2008-05-07 EP disclosed
US-20050250793-A1 Preventives/remedies for hot flash TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-11-10 US disclosed
EP-1495768-A1 PREVENTIVES/REMEDIES FOR HOTFLASH Takeda Pharmaceutical Company Limited (JP) 2005-01-12 EP disclosed
US-20040116522-A1 Medicinal solutions TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-06-17 US disclosed
EP-1163244-B1 THIENOPYRIMIDINE COMPOUNDS, THEIR PRODUCTION AND USE TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2004-03-10 EP disclosed
EP-1393747-A1 PREVENTIVES/REMEDIES FOR ALZHEIMER'S DISEASE Takeda Chemical Industries, Ltd. (JP) 2004-03-03 EP disclosed
US-20040034039-A1 Solid preparations TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-02-19 US disclosed
US-20040023987-A1 Sustained release compositions TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-02-05 US disclosed
EP-1374855-A1 MEDICINAL SOLUTIONS Takeda Chemical Industries, Ltd. (JP) 2004-01-02 EP disclosed
US-20030176360-A1 Medicinal preparations for treating sex hormone-dependent diseases TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-09-18 US disclosed
US-20030134863-A1 Preventives/remedies for alzheimer's disease TAKEDA CHEMICAL INDUSTRIES LTD. (JP) 2003-07-17 US disclosed
EP-1319409-A1 SOLID PREPARATIONS Takeda Chemical Industries, Ltd. (JP) 2003-06-18 EP disclosed
EP-1297850-A1 MEDICINAL PREPARATIONS FOR TREATING SEX HORMONE-DEPENDENT DISEASES Takeda Chemical Industries, Ltd. (JP) 2003-04-02 EP disclosed
EP-1291023-A1 SUSTAINED RELEASE COMPOSITIONS Takeda Chemical Industries, Ltd. (JP) 2003-03-12 EP disclosed
US-6340686-B1 GONADOTROPIN-RELEASING HORMONE ANTAGONISTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-01-22 US disclosed
US-6297379-B1 GONADOTROPIN RELEASING HORMONE (GNRH, SOMETIMES CALLED LH-RH (LUTEINIZING HORMONE RELEASING HORMONE)) ANTAGONIZING ACTIVITY, TREATING SEX HORMONE-DEPENDENT DISEASES. TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134863-A1 Preventives/remedies for alzheimer's disease ACHE, GNRHR, PSEN1 GNRHR 2/4885
US-20080207524-A1 MEDICINAL PREPARATIONS FOR TREATING SEX HORMONE-DEPENDENT DISEASES SHBG, GNRHR, NR5A1 GNRHR 2/4885
US-20040023987-A1 Sustained release compositions NGLY1, GHSR, GHRHR GNRHR 46/4885
US-20050250793-A1 Preventives/remedies for hot flash GNRHR, SHBG, FSHR GNRHR 1/4885
US-20040034039-A1 Solid preparations GYS1, GYS2, SI GNRHR 3501/4885
US-20090048273-A1 PREMATURE OVULATION PREVENTIVE AGENT GNRHR, FSHR, LHCGR GNRHR 1/4885
US-20030176360-A1 Medicinal preparations for treating sex hormone-dependent diseases SHBG, GNRHR, NR5A1 GNRHR 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.